Binance Alpha will remove 14 tokens from its trading platform on October 9, including SUP, CUDIS, PYTHIA, and others. While trading for these tokens will end, users can still sell or withdraw them after removal. This change affects trading support but does not restrict access to the tokens for holders. The tokens being removed come from various projects such as Superp, Kindred Labs, and Verasity.
The removal of 14 tokens from Binance Alpha provides context for cryptocurrency market activity on Pluang as of Oct 09, 2026 14:21 WIB. Among 50 major cryptocurrencies priced on Pluang, 13 rose and 36 fell today. Filecoin (FIL) gained 4.41% to Rp19.663 with a typical hold time of 99 days and a buy order activity of 64%, contrasting with Solana (SOL) which dropped 4.41% to Rp1.975.754 and The Sandbox (SAND) down 3.83% to Rp1.268, where SAND showed a higher sell order activity at 69%.
Wolters Kluwer repurchased 499 of its ordinary shares between October 29 and November 4, 2026, spending €0.04 million at an average price of €85.06 per share. This is part of a larger 2026 share buyback program aiming to repurchase shares worth up to...
Lorenz Snacks has introduced a fleet of four autonomous, electric vehicles from Einride at its production site in Neunburg vorm Wald, Germany. These vehicles will handle in-plant transport of goods and materials, replacing diesel trucks and significa...
Futu Holdings Limited will announce its financial results for the third quarter ending September 30, 2026, on November 19 before U.S. market open. The company will host a live earnings conference call at 7:30 AM ET (8:30 PM Beijing/Hong Kong time) th...
UBS Group AG notified Bang & Olufsen A/S that its shareholding and voting rights exceeded 5% as of October 30, 2026, but fell below 5% by November 2, 2026. As of November 2, UBS held 4.66% of Bang & Olufsen's total shares and voting rights. This chan...
T-Therapeutics secured $133 million in an oversubscribed Series B funding round led by Advent Life Sciences and British Business Bank to develop its first-in-class TCR-CD3 bispecific therapies targeting cancer and autoimmune diseases. The funds will ...
